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Abstract
AT-rich interactive domain 1A (ARID1A) has emerged as a new tumor suppressor in which frequent somatic muta-
tions have been identified in several types of human cancers. Although most ARID1A somatic mutations are frame-
shift or nonsense mutations that contribute to mRNA decay and loss of protein expression, 5% of ARID1Amutations
are in-frame insertions or deletions (indels) that involve only a small stretch of peptides. Naturally occurring in-frame
indel mutations provide unique and useful models to explore the biology and regulatory role of ARID1A. In this study,
we analyzed indel mutations identified in gynecological cancers to determine how these mutations affect the
tumor suppressor function of ARID1A. Our results demonstrate that all in-frame mutants analyzed lost their ability
to inhibit cellular proliferation or activate transcription of CDKN1A, which encodes p21, a downstream effector of
ARID1A. We also showed that ARID1A is a nucleocytoplasmic protein whose stability depends on its subcellular
localization. Nuclear ARID1A is less stable than cytoplasmic ARID1A because ARID1A is rapidly degraded by the
ubiquitin-proteasome system in the nucleus. In-frame deletions affecting the consensus nuclear export signal reduce
steady-state protein levels of ARID1A. This defect in nuclear exportation leads to nuclear retention and subsequent
degradation. Our findings delineate a mechanism underlying the regulation of ARID1A subcellular distribution and
protein stability and suggest that targeting the nuclear ubiquitin-proteasome system can increase the amount of
the ARID1A protein in the nucleus and restore its tumor suppressor functions.
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Introduction
Mutations in AT-rich interactive domain 1A (ARID1A) have been
detected in a wide variety of human cancers, most frequently in
endometrium-related carcinomas (e.g., ovarian clear cell carcinoma,
ovarian endometrioid carcinoma, and uterine endometrioid carci-
noma) [1–5] and subtypes of gastric carcinoma associated with
microsatellite instability or Epstein-Barr virus infection [6]. Most
ARID1A mutations are nonsense or out-of-frame mutations, which
lead to inactivation of the protein products; therefore, ARID1A is
thought to be a tumor suppressor. To directly demonstrate the role
of ARID1A in tumorigenesis, in a previous study, we restored wild-
type ARID1A expression in ovarian cancer cells that harbor deleteri-
ous ARID1A mutations. Our results showed that ARID1A expression
is sufficient to suppress cellular proliferation and tumor growth in
mice [7]. Moreover, silencing ARID1A expression in nontransformed
epithelial cells enhances cellular proliferation and tumorigenicity in a
mouse tumor xenograft model [7]. At the molecular level, ARID1A
forms a complex with BRG1, and this complex directly interacts with
p53 and regulates transcription of downstream effectors including
CDKN1A (p21) and SMAD3 through collaboration with p53 [7].
We analyzed sequence mutations of ARID1A reported in different
types of neoplasms and found that 5% of the mutations were small
in-frame insertions or deletions (indels). These indel mutations may
play a role in tumor suppression but may not directly affect protein
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expression as occurred with nonsense or frameshift mutations that
lead to mRNA or protein instability. Therefore, in-frame indels rep-
resent unique models for characterizing unknown mechanism(s) in
the regulation of ARID1A activity. Our results demonstrate that
ARID1A in-frame mutations alter cellular proliferation and CDKN1A
(p21) transcription and reveal mechanisms underlying the regulation
of ARID1A subcellular distribution and protein stability.
Materials and Methods
DNA Constructs
The vectors pLenti-puro and pcDNA6-V5/His.b containing wild-
type full-length ARID1A have been described previously [7]. Mutant
constructs DupPP, DupQ, DelL, and Del9 were generated by site-
directed mutagenesis using the pCDNA6-V5/His.b-ARID1A plas-
mid as template [7]. To generate the Del5A construct, the ARID1A
N-terminal fragment was amplified by polymerase chain reaction (PCR)
with T7 promoter primer and Del5A reverse primer (5′-GCCGCCG-
CAGCCCCCCAACACTG-3′) using pcDNA6-V5/His.b-ARID1A
as template. This fragment was then digested with NheI and cloned
into the pcDNA6-V5/His.b-ARID1A plasmid between the NheI site
and blunted NotI site. These five constructs were subcloned into the
pLenti-puro vector for production of lentivirus, as previously described
[7]. All ARID1A constructs used in this study contain V5/His tags at
the C terminus. The human influenza hemagglutinin (HA)–tagged
ubiquitin vector used in this study was previously described [8].
Cell Culture and Treatment
The ovarian surface epithelial cell line OSE4 [9] and ovarian clear
cell carcinoma cell line OVISE [10] were cultured in RPMI-1640
medium supplemented with 10% FBS. The ovarian clear cell carci-
noma cell line ES2 and human embryonic kidney cell line HEK293FT
(Invitrogen, Grand Island, NY) were maintained in high-glucose
Dulbecco’s modified Eagle’s medium with 10% FBS. Lentivirus express-
ing ARID1A was produced in HEK293FT cells using the second-
generation packaging system pSPAX2 (Addgene plasmid 12260) and
pMD2.G (Addgene plasmid 12259). Lentiviral titer was determined by
using quantitative PCR (qPCR) to measure viral RNA content in the viral
supernatant [11]. Lipofectamine 2000 and Lipofectamine LTX/plus
reagents (Invitrogen) were used to transfect the DNA constructs into
HEK293FT cells and OSE4 cells, respectively. The proteasome inhibitor
MG132 (Boston Biochem, Cambridge, MA) was used at 5 μM, protein
synthesis inhibitor cycloheximide (Sigma, St Louis, MO) at 10 μg/ml,
and nuclear export inhibitor leptomycin B (Sigma) at 10 ng/ml.
Cell Proliferation and Flow Cytometry Analysis
Cell proliferation was evaluated in 96-well plates as described pre-
viously [7]. To determine the number of cells in different phases of cell
cycle, we pulse labeled cells with 10 μM 5-ethynyl-2′-deoxyuridine
(EdU) for 2 hours using the Click-iT EdU kit (Invitrogen) according
to the manufacturer’s instruction. The EdU was subsequently detected
with Alexa Fluor 647 azide, and DNA was stained with CellCycle
405-blue. Cells were then analyzed by flow cytometry (BD LSR II flow
cytometer; BD Biosciences, San Jose, CA).
In Vivo Ubiquitination Assay
To determine the ubiquitination of ARID1A, we followed a pre-
viously published method [12]. Briefly, HEK293FT cells were co-
transfected with vectors expressing wild-type ARID1A or mutant
Del9 or DelL along with the HA-tagged ubiquitin expression vector.
Forty-eight hours after transfection, the cells were lysed in urea lysis
buffer (8 M urea, 100 mM NaH2PO4, 20 mM imidazole, pH 7.5).
The lysates were then incubated with 20 μl of nickel-nitrilotriacetic acid
(Ni-NTA) agarose resin (Qiagen, Valencia, CA) for 30 minutes at room
temperature. Proteins bound to the resin were washed with urea lysis
buffer, boiled in Laemmli buffer, separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, and analyzed by immunoblot analysis.
Cell Fractionation, Immunoprecipitation, and
Chromatin Immunoprecipitation
Nuclear and cytoplasmic lysates were prepared by using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce, Thermo Scientific,
Rockford, IL) with slight modifications to the manufacturer’s protocol.
Briefly, instead of using the nuclear extraction reagent provided, the nu-
clear pellet was solubilized by sonication in a 1:1 mixture of 2× Laemmli
buffer and NP-40 buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1%
NP-40). For coimmunoprecipitation of exportin 1 (XPO1) and ARID1A,
ES2 cells were treated with dimethyl 3,3′-dithiobispropionimidate
(Thermo Scientific) to cross-link proteins and then lysed in NP-40
buffer with 0.5% Triton. Antibody complexes were pulled down using
Protein A/G (1:1) magnetic beads (Dynabeads; Invitrogen).
Chromatin immunoprecipitation was performed with anti-V5 anti-
bodies (V8012, Sigma) using chromatin from OSE4 cells transfected
with the ARID1A DNA constructs. After transfection, OSE4 cells
were sequentially fixed with ethylene glycol bis(succinimidylsuccinate)
(Thermo Scientific) and 1% formaldehyde and lysed with chromatin
immunoprecipitation lysis buffer [1% sodium dodecyl sulfate, 10 mM
EDTA, and 50 mM Tris (pH 7.5)]. Binding of ARID1A to the
CDKN1A promoter was assessed by qPCR as previously described [7].
qPCR and Western Blot Analysis
Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen).
First-strand cDNA generated using the iScript cDNA synthesis kit
(Bio-Rad) was served as a template for qPCR. qPCR was performed
using the CFX96 Real-Time PCR Detection System (Bio-Rad) and
SYBR Green I reagents (Invitrogen). Primers used to amplify ARID1A
and CDKN1A (p21) were previously described [7]. The gene encoding
human large ribosomal protein (RPLP0) was used for normalization
(forward primer, 5′-GCAATGTTGCCAGTGTCTG-3′; reverse primer,
5′-GCCTTGACCTTTTCAGCAA-3′). The antibodies used for West-
ern blot analysis were ARID1A (HPA005456, Sigma-Aldrich), p53 (FL-
393, sc-6243; Santa Cruz Biotechnology, Santa Cruz, CA), p21 (DCS60,
#2946; Cell Signaling Technology, Danvers, MA), glyceraldehyde-3-
phosphate dehydrogenase (G9545, Sigma-Aldrich), V5 (R960-25,
Invitrogen), histone H3 (ab1791; Abcam, Cambridge, MA), XPO1
(named CRM1 in yeast, sc-5595, Santa Cruz Biotechnology), and mouse
anti-rabbit immunoglobulin G (IgG) (conformation specific; #3678, Cell
Signaling Technology). Signal intensities on films were quantified using
ImageQuant 5.2 software (Molecular Dynamics). Glyceraldehyde-3-
phosphate dehydrogenase and p53 were used as loading controls for
proteins in the cytoplasmic and nuclear fractions, respectively.
Results
In-frame Indel Mutations of ARID1A in Human Cancer
ARID1A mutations have been reported in a variety of human neo-
plasms [1–6,13,14]. In addition to those tumors in which ARID1A has
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already been sequenced, we sequenced an ovarian clear cell carcinoma
specimen, 1013T, and found that it contained two heterozygous muta-
tions: a frameshift mutation, p.1415Qfs, and an in-frame deletion,
p.L2009_L2017del (Del9). Among the 257 somatic ARID1A muta-
tions identified to date, we found that 62% were frameshift mutations,
and 24% were nonsense mutations (Figure 1A). Thus, approximately
86% of ARID1A mutations would result in reduced ARID1A protein
levels because of nonsense-mediated mRNA decay and/or degradation
of incorrectly folded truncated proteins. A closer look at the ARID1A
mutation spectrum revealed that 13 (5%) of 257 ARID1A mutations
involved small indels (Figure 1B and Table 1). Ten of the 13 indels were
unique, involving deletion or duplication at different locations in the
ARID1A protein. Of note, three tumors harbored the p.A344_A348del
mutation, two tumors harbored the p.Q1334del mutation, and two
tumors harbored mutations affecting codons located at the leucine-rich
(LxxxLxxLxL) nuclear export signal (NES) (Figure 1B).
ARID1A In-frame Indel Mutants Lose Ability to Suppress
Cellular Proliferation and Induce p21 Expression
To determine whether in-frame indel mutations of ARID1A retain
tumor suppressor function, we constructed expression vectors for all
in-frame indel mutations identified in gynecological cancers (Del9,
DelL, Del5A, DupPP, and DupQ; Table 1). For functional analysis
of the mutants, we used the ovarian clear cell carcinoma cell line
OVISE, because this cell line harbors biallelic ARID1A frameshift
mutations, which results in undetectable ARID1A protein expression
[1,7]. OVISE cells were transduced with lentivirus expressing wild-type
ARID1A or one of the in-frame indel mutant constructs. Compared
Figure 1. The spectrum of ARID1Amutations in human cancer. (A) Types of ARID1A mutations found in endometrium-related gynecologic
cancer, gastric cancer, and other cancer types. Different mutation types are indicated by different colors. (B) Diagram of in-frame indel
mutations. The five in-frame mutations identified in ovarian clear cell and endometrioid carcinomas are shown in bold font. The
p.A344_A348del mutation was detected in three independent tumors, and the p.Q1334del mutation was detected in two tumors. LXXLL,
leucine-rich steroid receptor binding motif; ARID, AT-rich interactive domain; NLS, nuclear localization signal; NES, nuclear export signal.
Table 1. In-frame Indel Mutations of ARID1A in Human Carcinomas.
Mutation Tumor Type Construct Name Reference
p.A344_A348del Ovarian endometrioid carcinoma Del5A [2]
p.P16_P17dupPP Ovarian clear cell carcinoma DupPP [2]
p.Q1334_R1335dupQ Ovarian clear cell carcinoma DupQ [1]
p.L2007del Ovarian clear cell carcinoma DelL [2]
p.L2009_L2017del Ovarian clear cell carcinoma Del9 This study
p.A344_A348del Gastric carcinoma Del5A [6]
p.Q1334del Gastric carcinoma N/A [6]
p.N982del Colorectal carcinoma N/A [4]
p.Q1334del Prostate carcinoma N/A [4]
p.I2135L2136del Lung carcinoma N/A [4]
p.S2191_G2193del Hepatocellular carcinoma N/A [13]
p.A344_A348del Hepatocellular carcinoma Del5A [13]
p.P478del Hepatocellular carcinoma N/A [14]
Del, deletion; dup, duplication.
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with control cells that expressed wild-type ARID1A, cells expressing in-
frame indel mutants showed attenuated growth inhibition, as de-
termined by growth curve analysis (Figure 2). Moreover, ectopic
expression of the in-frame indel mutants failed to increase the pro-
portion of cells at the G0/G1 phase, whereas G0/G1 phase arrest was
observed in cells expressing wild-type ARID1A. In fact, cell cycle dis-
tribution in cells transfected with indel mutants was similar to that of
cells transfected with the lacZ-expressing vector control (Figure 2F ).
Because CDKN1A (p21) is a direct target of the ARID1A chromatin
remodeling complex, and p21 plays a role in the tumor suppressor
function of ARID1A [7,15], we determined the effects of the in-frame
indel mutations of ARID1A on p21 expression. ARID1A mRNA levels
in cells transfected with wild-type ARID1A were similar to those of cells
transfected with the indel mutants (Figure 3A); however, CDKN1A
mRNA levels were markedly reduced in cells expressing the mutant
constructs (Figure 3B). Western blot analysis was performed to deter-
mine whether the reduced CDKN1A transcription in cells expressing
mutant ARID1A was because of reduced ARID1A protein levels. We
found that that cells expressing the Del9 and DelL mutants showed
reduced ARID1A protein expression, whereas cells expressing the
DelA, DupPP, and DupQ mutants showed ARID1A protein levels
similar to that of wild-type ARID1A (Figure 3C ). Interestingly, p21
protein levels were decreased in cells transfected with each of the
ARID1A in-frame indel mutants, including the mutations that did
not alter ARID1A protein expression (i.e., DelA, DupPP, and DupQ;
Figure 3C). We then evaluated whether chromatin remodeling com-
plexes containing the DelA, DupPP, and DupQ mutant proteins were
able to bind to CDKN1A promoter by performing ChIP-qPCR analy-
sis. Compared with wild-type ARID1A, mutants DelA, DupPP, and
DupQ exhibited significantly reduced binding activity to the CDKN1A
promoter (Figure 3D).
Degradation of ARID1A Protein by
Ubiquitin-Proteasome System
Because the DelL and Del9 mutants showed normal mRNA levels
but decreased steady-state protein levels, we evaluated the posttranscrip-
tional regulation of these two proteins. HEK293FT cells transfected
with vectors expressing wild-type or mutant ARID1A protein tagged
with the V5/His epitope were treated with the proteasome inhibitor
MG132 or vehicle control [dimethyl sulfoxide (DMSO)]. We found
that proteasome inhibition resulted in the accumulation of wild-type
ARID1A protein, indicating that the proteasome pathway was in-
volved in ARID1A degradation. In addition, in cells harboring the
DelL and Del9 mutants, MG132 treatment fully restored ARID1A
protein levels (Figure 4A). Taken together, our results suggest that
the reduced steady-state protein levels of DelL and Del9 mutants were
not related to translation efficiency or mRNA decay but to increased
proteasomal degradation.
Because ubiquitination typically precedes proteasomal degradation,
we determined whether ARID1A degradation was mediated by the
ubiquitin-mediated system. HA-tagged ubiquitin vector was trans-
fected into HEK293FT cells expressing wild-type ARID1A, DelL, or
Del9. The V5/His-tagged protein was enriched by purification with
nickel affinity beads and analyzed by Western blot analysis using anti-
V5 and anti-HA antibodies. We found that cells expressing Del9 and
DelL mutants showed higher levels of ARID1A ubiquitination than
Figure 2. Loss of tumor suppressor function of ARID1A in-frame mutations. (A–E) OVISE cells, which do not express detectable levels of
endogenous ARID1A protein, were infected with lentiviral vectors expressing wild-type or mutant ARID1A. Relative cell numbers were
determined at different days after lentiviral transduction. (F) Cell cycle progression was analyzed by flow cytometry after EdU incorporation
and DNA staining. The percentages of cells in different phases of cell cycle were determined.
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Figure 3. ARID1A mutants lose the ability to induce CDKN1A (p21) transcription. (A) Levels of ARID1A mRNA in cells expressing wild-
type ARID1A or in-frame indel mutants. Vector expressing lacZ was used as a negative control. (B) Levels of CDKN1A (p21) mRNA in cells
expressing wild-type ARID1A or in-frame mutants. Vector expressing lacZwas used as a negative control. (C) Western blot analysis shows
protein levels of ARID1A and p21 in cells expressing wild-type ARID1A and in-frame indel mutants. GAPDH was used as a protein loading
control. (D) Chromatin immunoprecipitation–qPCR analysis demonstrates the binding activity of wild-type ARID1A and in-frame indel
mutants Del 5A, Dup2P, and DupQ to the CDKN1A promoter. One-way t test, *P < 0.05; **P < 0.01.
Figure 4. Degradation of ARID1A by the ubiquitin-proteasome pathway. (A) Proteasome inhibition increases Del9 and DelL protein levels.
The residue deleted in the DelL mutant is indicated in bold, and residues deleted in the Del9 mutant are underlined. ARID1A constructs with
V5/His dual tags at the C terminus were introduced into HEK293FT cells. Twenty-four hours after transfection, cells were treated with
MG132 (proteasome inhibitor) or DMSO (vehicle control) for an additional 16 hours. ARID1A protein levels were determined by Western
blot analysis using an anti-V5 antibody (right), andARID1AmRNA levels (left) were determined by qPCR analysis. (B) Enhanced ubiquitination
of Del9 and DelL mutants as compared with the wild-type protein. HEK293FT cells were transfected with constructs expressing HA-tagged
ubiquitin (HA-Ub) and ARID1A-V5/His. ARID1A proteins were enriched using Ni-NTA agarose beads. The eluates were subjected toWestern
blot analysis using anti-V5 and anti-HA antibodies.
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cells expressing wild-type ARID1A (Figure 4B, right panel). Conversely,
lower levels of nonubiquitinated ARID1A were observed in cells ex-
pressing mutant proteins than in cells expressing wild-type ARID1A
(Figure 4B, left panel). These findings suggest that the DelL and
Del9 mutations lead to increased ubiquitination and subsequent pro-
teasomal degradation, resulting in the observed reduction in steady-state
ARID1A protein levels.
Protein Expression of Wild-type ARID1A and In-frame
Indel Mutants after Proteasome Inhibition
The DelL andDel9 mutations occurred at the conserved NES motif,
suggesting that these mutations inhibit nuclear export and facilitate
proteasomal degradation in the nucleus. To test this possibility, we
prepared cytosolic and nuclear fractions from OSE4 cells express-
ing wild-type ARID1A, DelL, or Del9. We found that cytoplasmic
ARID1A protein levels were considerably lower in cells expressing
DelL or Del9 than in cells expressing wild-type ARID1A, indicating
that the nuclear export of these two mutants was inhibited (Figure 5A).
In contrast, the cytoplasmic and nuclear distribution of ARID1A in
cells expressing Del5A, DupPP, and DupQ was similar to that of cells
expressing wild-type ARID1A (Figure 5B). After blocking proteasome
activity with MG132, the DelL and Del9 mutant proteins accumulated
in the nucleus to levels similar to that of wild-type ARID1A (Figure 5A).
We also noted that cytoplasmic ARID1A levels were slightly reduced
after MG132 treatment in all cells (expressing wild-type or mutant pro-
tein); this result may be because of nonspecific changes in the equilib-
rium distribution of proteins between the cytoplasm and nucleus on
MG132 treatment.
Cytoplasmic Pool of ARID1A Is More Stable than the
Nuclear Pool
To determine whether ARID1A degradation occurs primarily in the
nucleus, we evaluated the stability of wild-type ARID1A protein in the
cytosolic and nuclear compartments of OSE4 cells after inhibiting
protein synthesis with cycloheximide. Western blot analysis of the cel-
lular fractions showed no detectable decline in cytoplasmic ARID1A
protein for up to 90 minutes, whereas the level of nuclear ARID1A
protein decreased to 45% with a half-life of approximately 75 minutes
Figure 5. Localization of ARID1A protein in the nucleus and cytoplasm. (A) Steady-state levels of wild-type ARDI1A protein and the Del9
and DelL mutants in nuclear (N) and cytoplasmic (C) fractions. OSE4 cells were transfected with ARID1A constructs and treated with
MG132 (proteasome inhibitor) or DMSO (vehicle control). Ectopic ARID1A levels were determined by Western blot analysis using an
anti-V5 antibody. GAPDH and p53 served as loading controls for cytoplasmic and nuclear protein fractions, respectively. (B) Subcellular
distribution of the three ARID1A in-frame indel mutants in which the NES was not affected. (C, D) The half-life of cytoplasmic and nuclear
ARID1A was determined after inhibiting protein synthesis with cycloheximide (CHX). Histone H3 served as a nuclear protein loading
control. (E) Assessment of the half-life of ARID1A mutant proteins in cytosolic and nuclear compartments.
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(Figure 5, C and D). Using the same strategy, we further assessed the
stabilities of cytosolic and nuclear ARID1A proteins from different
mutants, Del5A, Dup2P, and DupQ. Del9 and DelL mutants were
not included because of their low steady-state protein levels. As shown
in Figure 5E , nuclear protein levels of all three ARID1A mutants
decreased rapidly after protein synthesis inhibition, while their levels
in cytosolic fraction remained relatively constant.
Next, we determined whether the cytoplasmic fraction of ARID1A
was nascent protein that had yet to be imported into the nucleus or
represented ARID1A exported from the nucleus. Because the leucine-
rich NES interacts with XPO1 (also named CRM1 in yeast) to form
an export complex [16], we determined whether ARID1A interacts with
XPO1 by coimmunoprecipitation of these proteins. For this assay, we
used ES2 cells, which express high levels of ARID1A [7]. ARID1A
was readily detected in immunoprecipitates pulled down with the
XPO1 antibody but not in immunoprecipitates pulled down with nor-
mal IgG (Figure 6A). Treatment with leptomycin B, a nuclear export
inhibitor that targets XPO1, markedly reduced cytoplasmic levels of
ARID1A protein (Figure 6B, lane 3). However, leptomycin B did not
increase nuclear ARID1A levels, in part because of rapid protein degra-
dation in the nucleus. In fact, in leptomycin B–treated cells, nuclear
ARID1A protein level was restored by treatment with proteasome
inhibitor MG132 (Figure 6B, lane 8).
Discussion
This study was undertaken to characterize all ARID1A in-frame indel
mutations that have been identified in gynecological cancers. Because
somatically acquired mutations are the result of natural selection
for more advantageous tumor growth, structural changes in the mu-
tant proteins may likely attenuate the tumor suppression function of
ARID1A. In fact, we demonstrated that these indel mutants lack the
ability to inhibit cellular proliferation or activate p21 transcription, the
two main functions of wild-type ARID1A known so far [7]. We fur-
ther showed that in-frame indel deletions involving the NES lead to
the nuclear retention, increased ubiquitination, and subsequent degra-
dation by the ubiquitin-proteasome pathway. The findings reported
here demonstrate the regulatory mechanism involving ARID1A protein
stability and set an example that studying naturally occurring mutations
may elucidate the underlying biology of that protein.
In-frame indel mutations of ARID1A can be divided into two groups
according to mechanisms underlying suppression of its tumor sup-
pressor function. The first group of mutations is exemplified by Del9
and DelL, in which the NES sequence is disrupted by in-frame dele-
tions, resulting in reduced nuclear export. The mutant proteins are
more highly ubiquitinated, which may lead to more rapid degradation
than wild-type ARID1A. The second group of mutant proteins in-
cludes DelA, DupPP, and DupQ, in which mutations do not occur
at the NES or any known protein domain of ARID1A (Figure 1B).
The amino acid changes in DelA, DupPP, and DupQ do not alter pro-
tein stability significantly; these mutant proteins bind with lower af-
finity to the CDKN1A promoter compared with wild-type ARID1A,
suggesting that the residues deleted or duplicated in these three mu-
tants are important for promoter binding. Alternatively, the residues
may be important for interactions between ARID1A and the other
switch/sucrose nonfermentable subunits in the ARID1A chromatin
remodeling complex and mutations at these residues may disturb the
stability of the whole protein complex.
In addition to the leucine-rich NES, which mediates the transport
of large molecules through the nuclear pore complex, ARID1A also
contains a classical nuclear localization signal [17], PVLKQRR (amino
acids 1651–1657), which targets ARID1A protein to the nucleus.
Therefore, it is likely that a highly dynamic balance between nuclear
trafficking and nuclear proteasomal degradation is required to maintain
the appropriate level of ARID1A in the nucleus, where it functions as
a chromatin remodeler and tumor suppressor. Our data in Figure 5C
indicate that ARID1A degradation happens mainly in the nucleus.
It has been established that the cell nucleus contains the components
of the ubiquitin-proteasome system, which include the ubiquitin-
conjugating enzymes (E1, E2s, and E3s) and the 26S proteasome
(including 19S and 20S subunits) [18]. The ubiquitin-proteasome
system in the nucleus was shown to control the localization, quantity,
and transcriptional activity of the transcriptional complexes [19]. For
example, the proteolytic activity of the 20S proteasome was found to
facilitate transcriptional elongation by mediating turnover of promoter-
bound activators and allowing the initiating RNA polymerase to escape
from the promoter [20,21]. We speculate that rapid ARID1A turn-
over in the nucleus might be integral to its dynamic function of chro-
matin remodeling and transcription regulation. So far, the ubiquitin
ligase responsible for ARID1A ubiquitination has not been identified.
Figure 6. XPO1-dependent ARID1A nuclear export. (A) ES2 cell lysate was immunoprecipitated using a rabbit anti-XPO1 antibody or
normal rabbit IgG. Total cell extracts (input) and immunoprecipitates were then probed using antibodies against XPO1 or ARID1A fol-
lowed by a mouse anti-rabbit conformation-specific antibody. (B) Nuclear and cytoplasmic levels of ARID1A were determined in OSE4
cells transfected with wild-type ARID1A. Sixteen hours after transfection, cells were treated with leptomycin B (LMB) for an additional
24 hours; during the last 6 hours of incubation, MG132 was added to some of the cells as indicated. Protein levels of ARID1A-V5 were
detected by Western blot analysis with an anti-V5 antibody. GAPDH and p53 served as loading controls for cytoplasmic and nuclear
protein fractions, respectively.
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However, a close homolog of ARID1A (ARID1B) is part of an E3
ligase complex that targets histone H2B [22], suggesting that ARID1A
may ubiquitinate itself.
Although this study provides new insights into the effect of in-frame
indels on the biological functions of ARID1A, several limitations of
this study should be pointed out. First, we did not characterize all
10 unique in-frame indels identified to date but focused only on the
five in-frame indels identified in gynecological cancer. It would be
interesting to know whether the mutations that were not characterized
in this report also show similar loss-of-function phenotypes. Second,
the switch/sucrose nonfermentable complex containing ARID1A is
composed of many subunits. Therefore, future studies are needed to
understand how in-frame indels that do not involve the NES con-
tribute to loss of function by determining if those mutations affect
protein-protein interaction between ARID1A and other subunits in
the complex or affect interaction between ARID1A complex and
DNA. Finally, because ARID1A protein stability is largely regulated by
the nuclear ubiquitin-mediated proteasome system, it would be inter-
esting to test whether stabilizing nuclear proteins including ARID1A
with specific ubiquitin-proteasome inhibitors exerts antitumor effects.
In summary, we demonstrated that in-frame indel mutations of
ARID1A, like frameshift and nonsense mutations, are associated
with the loss of ability to suppress cellular proliferation and activate
CDKN1A (p21) transcription. These effects are mediated by increased
protein degradation in the nucleus or reduced CDKN1A promoter
binding. Our findings provide new evidence that ARID1A is a nucleo-
cytoplasmic protein, and structural disruption of the NES results in
retention of ARID1A in the nucleus, where it is subject to ubiquitin-
proteasomal degradation. These results may have important impli-
cations for understanding the biology of ARID1A and its role as a
tumor suppressor.
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